A case series of 15 patients with NSCLC with EGFR mutations and CNS metastases who received cerebrospinal fluid concentration (CSF) examinations during EGFR TKI treatment provides further evidence to support this conclusion. This evidence concerns the gene EGFR and non-small cell lung carcinoma.